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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and
systemic inflammation which flare-up during episodes of acute exacerbation (AECOPD). Given the
role of Toll-like receptors (TLRs) in the induction of inflammatory responses we investigated the
involvement of TLRs in COPD pathogenesis.
Methods:  The expression of TLR-2, TLR-4 and CD14 in monocytes was analyzed by flow
cytometry. To study the functional responses of these receptors, monocytes were stimulated with
peptidoglycan or lipopolysaccharide and the amounts of TNFα and IL-6 secreted were determined
by ELISA.
Results: We found that the expression of TLR-2 was up-regulated in peripheral blood monocytes
from COPD patients, either clinically stable or during AECOPD, as compared to never smokers
or smokers with normal lung function. Upon stimulation with TLR-2 ligand monocytes from COPD
patients secreted increased amounts of cytokines than similarly stimulated monocytes from never
smokers and smokers. In contrast, the expressions of TLR-4 and CD14 were not significantly
different between groups, and the response to lipopolysaccharide (a TLR-4 ligand) stimulation was
not significantly different either. At discharge from hospital TLR-2 expression was down-regulated
in peripheral blood monocytes from AECOPD patients. This could be due to the treatment with
systemic steroids because, in vitro, steroids down-regulated TLR-2 expression in a dose-dependent
manner. Finally, we demonstrated that IL-6, whose plasma levels are elevated in patients, up-
regulated in vitro TLR-2 expression in monocytes from never smokers.
Conclusion: Our results reveal abnormalities in TLRs expression in COPD patients and highlight
its potential relationship with systemic inflammation in these patients.
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Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by an abnormal inflammatory response of the
lungs to noxious particles or gases, primarily cigarette
smoking, albeit not all smokers develop the disease [1].
COPD is also associated with systemic inflammation [2],
which is likely to contribute significantly to some impor-
tant extra-pulmonary consequences of COPD [1], namely
cardiovascular disease [3] and cachexia [4,5]. Both, pul-
monary and systemic inflammation, flare-up during the
episodes of acute exacerbation (AECOPD) that occur
often in these patients [1]. It is generally accepted that
some form of bacterial and/or viral infection is the main
cause of AECOPD [6], but the precise molecular mecha-
nisms underlying these episodes have not been fully char-
acterized [7]. Further, the relationship between bacterial
airway colonization and the abnormal pulmonary and
systemic inflammatory response that characterizes COPD
is unclear.
Mammalian Toll-like receptors (TLR) comprise a family of
germ line-encoded trans-membrane receptors which rec-
ognize conserved microbial structures, the so called path-
ogen-associated molecular patterns (PAMPs) [8].
Activation of TLRs leads to the induction of inflammatory
responses and to the development of antigen specific
adaptive immunity [8,9]. Among this family of receptors,
TLR-2 and TLR-4 have received great attention. TLR-4 is
essential for the recognition of lipopolysaccharide (LPS),
a major component of Gram-negative bacteria, whereas
TLR-2 recognizes a large number of ligands including bac-
terial lipotheicoid acid and lipoproteins [8]. CD14 is a 55-
kDa GPI-linked glycoprotein that also participates in
pathogen recognition and uses TLRs as co-receptors in sig-
nal transduction [10]. It has been shown that microbial
components interact primarily with CD14 and subse-
quently with the TLRs [11].
Because many patients with stable COPD present airway
colonization [12,13] and bacterial infection is a key trig-
ger of AECOPD [6], we hypothesized that TLR may partic-
ipate in the regulation of inflammation in COPD,
particularly during the episodes of AECOPD. To investi-
gate it, we first compared the expression of TLR-2, TLR-4
and CD14 in circulating monocytes harvested from
COPD patients (both during AECOPD and when clini-
cally stable), smokers with normal lung function and
never smokers. Then, we investigated the functionality of
these receptors upon stimulation with specific ligands.
Finally, we studied the effect of steroids, a drug routinely
used in the treatment of AECOPD [1], and IL-6, a cytokine
known to be elevated in the systemic circulation of COPD
patients [2], upon the expression of TLR-2, TLR-4 and
CD14.
Methods
Population and ethics
All participants gave their written consent after being fully
informed of the study, which was previously approved by
the Ethics Committee of our institution. Patients with
COPD were considered clinically stable if they had not
had an AECOPD episode and/or had required a change in
their usual therapy during the last 3 months. COPD
patients were treated with long-acting inhaled bronchodi-
lators and 6 received inhaled steroids but none was under
oral steroid therapy. Subjects with atopic diseases, allergic
rhinitis and asthma were excluded. To avoid any potential
effect of acute smoking, active smokers refrained from
smoking 12 hours before examination; exhaled carbon
monoxide concentration was lower than 10 ppm in all
subjects. Patients with AECOPD were studied within the
first 24 hours of hospital admission; at discharge and 3
months later, when clinically stable again. Healthy sub-
jects and smokers with normal lung function were
recruited from the pulmonary function laboratory of our
institution.
Because of the small volume of blood collected (5 to 8
ml), we could not perform all the analysis for each patient
and therefore the cell stimulation experiments were per-
formed only with a small group of them. Indeed, perform-
ing all the experiments with the cells of the same patient
was not allowed by the Ethics Committee because of the
large blood volume (30 ml) needed and since many of
Table 1: Clinical and functional data of the subjects included in this study.
Never smokers (n = 22) Smokers with normal 
lung function (n = 20)
Stable COPD Patients 
(n = 13)
AECOPD Patients (n = 
20)
Age (years) 57.8 ± 6.3 59.0 ± 1.9 60.0 ± 2.0 65.0 ± 2.0*
Smoking history (pack 
years)
0 43.1 ± 3.2 46.0 ± 3.0 65.0 ± 6.0
FEV1 (% ref) 95.8 ± 5.1 93.0 ± 2.5 58.0 ± 2.0+ 38.0 ± 3.0†
FEV1/FVC (%) 81.8 ± 2.5 75.0 ± 1.0 56.0 ± 2.0+ 46.0 ± 2.0†
* p < 0.05 (AECOPD vs stable COPD, smokers with normal lung function and never smokers)
†p < 0.01 (AECOPD vs stable COPD, smokers with normal lung function and never smokers)
+p < 0.01 (stable COPD vs smokers with normal lung function and never smokers)Respiratory Research 2006, 7:64 http://respiratory-research.com/content/7/1/64
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them was hospitalized due to a worsening of their clinical
status.
Bacterial isolation
AECOPD and COPD patients spontaneously expectorated
sputum samples when the clinics visit. Samples were
homogenized, diluted, and plated for identification as
previously described [6,14]. Patients did not receive anti-
biotics prior to sputum cultures.
Lung function
Forced spirometry (GS, Warren E. Collins, Braintree, MA,
USA) was obtained in all participants according to inter-
national guidelines [15]. Spirometric reference values
were those of a Mediterranean population [16].
Purification of peripheral blood monocytes
Peripheral blood mononuclear cells were purified by cen-
trifugation on Ficoll-Hypaque, and monocytes were
obtained using a commercial isolation kit exactly as rec-
ommended by the manufacturer (Dynal monocyte nega-
tive isolation kit, Oxoid). Lymphocytes represented less
than 5% of the cells after this procedure. Cells were finally
resuspended at a cell density of 106 cells/ml in RPMI-1640
medium supplemented with 10% heat inactivated Fetal
Calf Serum (FCS), glutamine (2 mM), HEPES (200 mM)
and antibiotics (penicillin-streptomycin). These purified
monocytes were used for the experiments shown in fig-
ures 2, 4 and 5.
Flow cytometry
Expression of CD14, TLR-2 and TLR-4 in peripheral blood
monocytes was determined by flow cytometry. Blood
samples (one sample per patient) were collected by
peripheral venipuncture and incubated during 30 min-
utes at 4°C with a combination of anti-CD14 FITC conju-
gated (clone My4, 10 µg/ml; Beckman Coulter) and anti-
TLR-2 (clone TL2.1, 10 µg/ml; ebioscience) or anti-TLR-4
(clone HTA125, 10 µg/ml; ebioscience) PE conjugated.
Monocytes were identified by gating on a side versus
CD14 dot plot.
Expression of CD14, TLR-2 and TLR-4 in purified mono-
cytes treated with IL-6 or steroids (results shown in figures
4 and 5) was also determined by flow cytometry. Mono-
cytes were detached from the wells with a rubber police-
man, washed with 0.1 % sodium-azide in PBS and
incubated with the antibodies exactly as indicated before.
The analyses were carried out in an Epics XL flow cytome-
ter using the Expo32 software. The levels of CD14, TLR-2,
TLR-4 were expressed as mean fluorescence intensity (mfi)
measured in arbitrary units and the non specific binding
was corrected by subtraction of mfi values corresponding
to isotype matched antibodies. A minimum of 3500
monocytes were analyzed in every experiment.
Cell culture and stimulation
Cells were cultured in 96 well plates at a cell density of 105
per well. Cells were stimulated with 100 ng/ml of lipopol-
ysaccharide (LPS) purified from Escherichia coli O111:B4
(Sigma Chemicals). This LPS was repurified exactly as pre-
viously described [17]. This procedure results in entero-
bacterial LPS preparations that utilize TLR-4, and not TLR-
2, for signalling [17]. Cells were also stimulated with 1 µg/
ml of peptydoglycan (PGN) purified from Staphylococcus
aureus (Merck). This PGN preparation does not stimulate
stably transfected TLR4-MD2-CD14 HEK293 cells (data
not shown) and it is also a poor activator of the intracel-
lular receptor NOD2 [18]. Recently it has been shown that
the commercial PGN preparation used in this work con-
tains lipoteichoid acid which is the true TLR-2 agonist
[18]. Perusal of the literature shows that the concentra-
tions of TLR agonists used in this study optimally stimu-
late human monocytes (for example see [19]). After 16
hours cell culture supernatants were collected, cell debris
were removed by centrifugation, and samples were frozen
at -80°C until assayed
Analysis of the expression of TLR-2 (panel A), TLR-4 (panel  B) and CD14 (panel C) in peripheral blood monocytes from  never smokers (n = 22), AECOPD (n = 20) and COPD (n =  13) patients and smokers (n = 20) Figure 1
Analysis of the expression of TLR-2 (panel A), TLR-4 (panel 
B) and CD14 (panel C) in peripheral blood monocytes from 
never smokers (n = 22), AECOPD (n = 20) and COPD (n = 
13) patients and smokers (n = 20). Shaded area represents 
TLR staining of monocytes from a representative AECOPD 
patient. The un-shaded area outlined by the darker line rep-
resents TLR staining in monocytes from a representative 
never smoker. The un-shaded area outlined by a thin line 
represents isotype matched PE labelled antibodies staining in 
monocytes from the AECOPD patient. The results were ana-
lyzed by one-way analysis of variance with Bonferroni con-
trasts.
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Cytokine quantification
We determined the concentration of IL-6 and TNFα in cell
culture supernatants or in plasma, using a bead array
ELISA according to the instructions of the manufacturer
(CBA Kit, BD Biosciences). The assay sensitivity for IL-6
was 2.5 pg/ml and for TNFα was 3.7 pg/ml.
Statistical analysis
Results are expressed as mean ± SD. The results were ana-
lyzed by paired two-tailed t test or one-way analysis of var-
iance with Bonferroni contrasts using GraphPad Prism
software (GraphPad Sotware Inc.). A p value lower than
0.05 was considered significant.
Results
Clinical data
Table 1 shows the clinical and functional data of subjects
included in the study. AECOPD patients were older than
the other groups (Table 1). Patients with COPD had mod-
erate-severe airflow obstruction, particularly those with
AECOPD whereas, by design, lung function was normal
in the other two groups of subjects studied (Table 1).
TLR expression
Figure 1 shows that, at admission, peripheral blood
monocytes from AECOPD patients expressed significantly
more TLR-2 than never smokers (6.78 ± 2.09 mfi vs. 4.01
± 1.94 mfi respectively; p = 0.001) (fig 1 panel A) whereas
the expression levels of TLR-4 were not significantly differ-
ent (2.32 ± 1.4 mfi vs. 2.80 ± 1.85 mfi, respectively, p =
0.36) (fig 1 panel B). Bacteria were isolated from the spu-
tum of only 4 AECOPD patients and in all cases the organ-
ism was identified as nontypable Haemophilus influenzae.
In these subjects, the expression levels of TLR-2 (5.72 ±
0.6 mfi) and TLR-4 (2.3 ± 0.5 mfi) were not different from
the other patients with AECOPD. Analysis of TLRs expres-
sion in peripheral blood monocytes from stable COPD
patients revealed that TLR-2 expression was also up-regu-
lated compared to never smokers (6.02 ± 1.9 mfi vs. 4.01
± 1.94 mfi; p = 0.01) (fig 1 panel A) and not significantly
different to that found in AECOPD patients at admission
(5.94 ± 2.12 mfi vs 6.78 ± 2.09 mfi respectively; p = 0.28).
TLR-4 expression (2.25 ± 1.34 mfi) was not significantly
different to that of AECOPD (p = 0.34) or never smokers
(p = 0.88) (fig 1 panel B). TLR-2 expression in smokers
with normal lung function was not significantly different
to that found in never smokers (3.40 ± 0.5 mfi vs 4.01 ±
1.94 mfi, respectively, p = 0.75) (fig 1 panel A) and this
was also the case when the expression of TLR-4 was com-
pared in these two groups (2.42 ± 2.14 mfi vs 2.80 ± 1.85
mfi, respectively, p = 0.71) (fig 1 panel B). However,
monocytes from smokers expressed significantly less TLR-
2 than monocytes from AECOPD patients (3.40 ± 0.5 mfi
vs 6.78 ± 2.09 mfi, respectively, p = 0.001) and monocytes
from COPD patients (3.40 ± 0.5 mfi vs 6.02 ± 2.09 mfi,
respectively, p = 0.02). In contrast, TLR-4 expression was
not significantly different to that of AECOPD (p = 0.71) or
COPD (p = 0.64) (fig 1 panel B). Finally, monocytes from
AECOPD patients expressed similar amounts of CD14
(407 ± 70.76 mfi) than monocytes from never smokers
(395 ± 117.2 mfi), stable COPD patients (439 ± 116.8 mfi)
or smokers (422 ± 154.4 mfi) (fig 1, panel C).
TLR functionality
To study the functional response of TLRs, purified mono-
cytes harvested from AECOPD patients at admission, sta-
ble COPD patients, smokers or never smokers were
stimulated with PGN or highly purified LPS (stimuli that
signal through TLR-2 and TLR-4 respectively) and the
amounts of TNFα and IL-6 secreted taken as read-out for
monocyte activation. No differences were observed in the
amount of TNFα secreted by unstimulated monocytes
from never smokers, smokers, AECOPD and COPD
patients (20 ± 4 pg/ml, 27 ± 9 pg/ml 24 ± 8 pg/ml and 22
± 4 pg/ml respectively). The basal secretion of IL-6 was
Levels of TNFα and IL-6 secreted into culture medium by  purified monocytes from never smokers (5 subjects; purified  cells from each subject were tested in triplicate), smokers (5  subjects; purified cells from each subject were tested in tripli- cate), AECOPD patients (AECOPD, 5 subjects; purified cells  from each subject were tested in triplicate) and COPD  patients (COPD, 5 subjects; purified cells from each subject  were tested in triplicate) Figure 2
Levels of TNFα and IL-6 secreted into culture medium by 
purified monocytes from never smokers (5 subjects; purified 
cells from each subject were tested in triplicate), smokers (5 
subjects; purified cells from each subject were tested in tripli-
cate), AECOPD patients (AECOPD, 5 subjects; purified cells 
from each subject were tested in triplicate) and COPD 
patients (COPD, 5 subjects; purified cells from each subject 
were tested in triplicate). Monocytes were stimulated with 1 
µg/ml of peptydoglycan (PGN) and supernatants were ana-
lyzed for TNFα(panel A) or IL-6 (panel B). Monocytes were 
stimulated with 100 ng/ml of LPS and supernatants were ana-
lyzed for TNFα(panel C) or IL-6 (panel D). The results were 
analyzed by one-way analysis of variance with Bonferroni 
contrasts. Symbols: * significant difference (p < 0.05) versus 
never smokers; ∆ significant difference (p < 0.05) versus 
smokers.
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also similar in the three groups (110 ± 10 pg/ml, 127 ± 22
pg/ml, 95 ± 8 pg/ml and 116 ± 15 pg/ml respectively). Fig-
ure 2 (panels A and B) shows that monocytes from
AECOPD (n = 5) and stable COPD (n = 5) stimulated
with PGN secreted significantly higher amounts of both
cytokines than similarly treated monocytes obtained from
never smokers (n = 5) and smokers (n = 5). Monocytes
from never smokers secreted similar amounts of both
cytokines than monocytes from smokers. When LPS was
used as stimulus, monocytes from patients secreted simi-
lar amounts of both cytokines than monocytes obtained
from never smokers or smokers (fig 2, panels C and D).
These results are in agreement with the fact that TLR-2
expression, but not that of TLR-4, was up-regulated in
monocytes from AECOPD and stable COPD patients. We
did not find significant differences in the secretion of
cytokines between monocytes harvested from AECOPD or
stable COPD patients independently of the stimuli used.
Effect of steroids on TLR expression
According to international guidelines [1], patients with
AECOPD were treated during hospitalization with intra-
venous steroids (methylprednisolone 2 mg/Kg/day dur-
ing 3 days with a progressive reduction of the drug in the
following 11 days), bronchodilator (salbutamol 2.5–5 mg
every 6 h) and antibiotics (levofloxacin 500 mg/day dur-
ing 7–10 days or amoxicillin-clavulanic acid 875 mg/8 h
during 7–10 days). In parallel, we found a significant
reduction of TLR-2 expression in AECOPD patients stud-
ied at discharge (fig 3 panel A) that was no longer different
from that of never smokers (5.56 ± 2.20 mfi vs 4.01 ± 1.94
mfi respectively; p = 0.11). In contrast, neither the expres-
sion of TLR-4 (fig 3 panel B) nor that of CD14 (fig 3 panel
C) changed during hospitalization. In 6 of these AECOPD
patients, TLR-2 expression was monitored 3 months after
hospital discharge and an increase in TLR-2 expression
was found (7.02 ± 1.52 mfi). Actually, these levels were
not significantly different from those determined in
AECOPD patients at admission (7.02 ± 1.52 mfi vs 6.78 ±
0.47  mfi  respectively; p = 0.31), suggesting that TLR-2
downregulation is transient.
To further characterize the effect of steroids upon TLR-2
expression, monocytes harvested from patients with
AECOPD (5 different patients) were incubated in vitro
with increasing doses of methylprednisolone (3 h; 0.01 to
1 µM). We found that steroids down-regulated the expres-
sion of TLR-2 in a dose-dependent fashion (fig 4). A sim-
ilar effect was seen when dexamethasone was used instead
of methylprednisolone (data not shown).
Role of systemic inflammation in TLRs expression
We found that the plasma concentration of IL-6 was sig-
nificantly higher in sera from AECOPD patients (5.19 ±
1.03 pg/ml) and stable COPD patients (5.75 ± 0.86 pg/
ml) than in never smokers (2.61 ± 0.13 pg/ml, p = 0.02).
To investigate the functional role of IL-6 upon TLRs
expression, purified monocytes from never smokers were
incubated in the presence of IL-6 and TLRs expression was
evaluated by flow cytometry. Figure 5 shows that IL-6 up-
regulated the expression levels of TLR-2 (panel A; 10 ± 1.2
mfi in the presence of IL-6 versus 3.8 ± 0.9 mfi in absence
of IL-6; p = 0.001) whereas the levels of TLR-4 (panel B;
2.5 ± 1.3 mfi in the presence of IL-6 versus 2.2 ± 0.5 mfi in
the absence of IL-6; p > 0.05) and CD14 (data not shown)
were unaffected. In parallel experiments we observed that
neither IL-8 nor IL-1β modified TLR-2 expression (data
not shown), thereby arguing against a general non-spe-
cific effect due to the incubation of monocytes with
cytokines.
Discussion
This study shows that the expression of TLR-2 was up-reg-
ulated in peripheral blood monocytes harvested from
COPD patients, either when clinically stable or during an
exacerbation of the disease, as compared to never smokers
or smokers with normal lung function. Furthermore,
upon stimulation with agonist signalling through TLR-2,
monocytes from COPD patients secreted increased
amounts of IL-6 and TNFα than similarly stimulated
monocytes from never smokers and smokers with normal
lung function. In contrast, the expressions of TLR-4 and
CD14 were not significantly different between groups and
the response to LPS stimulation (a TLR-4 specific ligand)
was not significantly different. We also showed that at dis-
charge, TLR-2 expression was down-regulated in periph-
Analysis of TLR-2 (panel A), TLR-4 (panel B) and CD14  (panel C) expression in peripheral blood monocytes from  AECOPD patients at admission (open circles) and hospital  discharge (black circle) Figure 3
Analysis of TLR-2 (panel A), TLR-4 (panel B) and CD14 
(panel C) expression in peripheral blood monocytes from 
AECOPD patients at admission (open circles) and hospital 
discharge (black circle). The results were analyzed by paired 
two-tailed t test.
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eral blood monocytes from AECOPD patients. This could
be due to the treatment with systemic steroids because, in
vitro, steroids down-regulated TLR-2 expression in a dose-
dependent manner. Finally, we demonstrated that IL-6,
whose plasma levels are elevated in patients, up-regulated
TLR-2 expression in vitro in purified monocytes from
never smokers, thereby connecting the systemic inflam-
mation that characterizes COPD and TLR-2 expression.
Altogether, these findings may be relevant for a better
understanding of, first, the mechanisms triggering the
abnormal inflammatory response that characterizes
COPD, particularly during the episodes of AECOPD, and,
second, the molecular effects of some therapeutic options
available to date.
TLRs are key molecules in host defence against microbial
pathogens. TLRs recognize pathogen-associated molecu-
lar patterns (PAMPs) who trigger the expression of proin-
flammatory genes and the development of antigen
specific adaptive immunity [8,9]. Most of our current
knowledge of TLR signalling has emerged from studies of
gene-targeted mice [8,9]. The contribution of TLR func-
tion to human disease is less advanced [20]. So far
research has mainly focused on the relationship between
presence of TLRs polymorphisms and susceptibility to a
disease [20]. Since the available data indicate that there
would not be a TLR polymorphism associated with COPD
[21] in this study we analyzed whether the expression
and/or functionality of TLRs was altered. We reasoned
that the increased secretion of inflammatory mediators
found in COPD patients could be due to an up-regulation
of TLRs expression. This hypothesis was based on studies
showing that macrophages overexpressing TLRs release
higher amount of inflammatory mediators upon TLR
engagement [22,23]. Indeed we found that TLR-2 (but not
TLR-4) expression was up-regulated in monocytes of
COPD patients (both when clinically stable and during
AECOPD), and that these cells secreted elevated levels of
inflammatory mediators upon challenge with prepara-
tions containing TLR-2 agonists (but not with LPS) (fig 2).
However it could be possible that the upregulation of
TLR-2 could not be the only explanation behind the
increased levels of inflammatory mediators. Thus differ-
ent levels of molecules of the TLR intracellular signalling
pathway might also account for the increased secretion of
mediators. However this possibility seems unlikely given
the facts that TLR-2 only transduces the signal via the
MyD88-dependent signalling pathway which is also used
by TLR-4 [24] and that TLR-4 dependent responses were
not affected. On the other hand, recently it has been
shown that NOD2 recognizes PGN [25,26] and therefore
activation of NOD2 dependent signalling pathway might
also account for our results. However it is important to
note that activation of this receptor requires an intracellu-
lar presentation of PGN which it is not the case in our
experimental set up. Nevertheless it cannot be ruled out
that function and/or expression of the elements of this sig-
nalling pathway could be altered in COPD patients.
Future studies will address this issue.
TLR-2 up-regulation in peripheral blood monocytes can
contribute significantly to the systemic inflammation that
occurs in COPD patients [5]. Interestingly, Riordan et al
[27] have reported similar findings in patients with liver
cirrhosis, a disease that, like COPD, is associated with sys-
temic inflammation. The airways of patients with stable
COPD are often colonized by bacteria, and bacterial path-
ogens (mainly nontypable Haemophilus influenzae and
Streptococcus pneumoniae) can be isolated in more than
70% of AECOPD [6]. Importantly, PAMPs of these patho-
gens activate inflammatory responses via TLR-2 among
other TLRs [28,29]. These bacteria are highly fragile and
tend to autolysis, thereby facilitating that their PAMPs
reach the systemic circulation. Hence, PAMPs-mediated
activation of monocytes via TLR-2 can contribute to the
systemic inflammation of COPD. Likewise, TLRs also rec-
ognize endogenous ligands ("danger signals") produced
by cells undergoing stress or necrosis [30,31]. Considering
that COPD is characterized by considerable tissue injury
Effect of methylprednisolone on the expression of TLR-2 by  monocytes from AECOPD patients (5 different patients;  purified cells from each subject were tested in duplicate for  each condition studied) Figure 4
Effect of methylprednisolone on the expression of TLR-2 by 
monocytes from AECOPD patients (5 different patients; 
purified cells from each subject were tested in duplicate for 
each condition studied). Purified monocytes were incubated 
for 3 h with different amounts of methylprednisolone and 
TLR-2 expression was studied by flow cytometry. For statis-
tical comparisons, TLR-2 expression by monocytes from 5 
representative never smokers after 3 h culture without stim-
uli is included in the figure. The results were analyzed by 
one-way analysis of variance with Bonferroni contrasts.
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[32], it is also possible that these endogenous ligands
could engage TLRs and contribute to systemic inflamma-
tion even in the absence of bacterial PAMPs.
Several potential mechanisms can contribute to up regu-
late TLR-2 in monocytes from COPD patients. Smoking is
not likely to be one of them because cells from smokers
with normal lung function expressed similar amounts of
TLR-2 than cells from never smokers (fig 1). Bacterial
PAMPs may also contribute to TLR-2 upregulation in
patients. In fact, it has been shown that the PAMPs'of H.
influenzae up-regulate TLR-2 expression but not that of
TLR-4 in eukaryotic cells [33]. Yet, sputum cultures in the
majority of patients studied here were negative, although
it is known that airway bacterial colonization can occur
despite the negativity of sputum cultures [34]. Finally,
inflammatory cytokines may also alter TLRs expression
[35]. Indeed, we found that IL-6 up-regulated TLR-2
expression  in vitro in monocytes obtained from never
smokers (figure 5). Thus, it is possible that the pro-inflam-
matory milieu known to occur in COPD has a similar
effect.
One limitation of our study is that we have not evaluated
whether TLR-2 expression is up-regulated in other periph-
eral blood cells. Sabroe et al [36] have shown that neu-
trophils and basophils express TLR-2 and TLR-4 albeit at
lower levels than monocytes. Of note these authors dem-
onstrated that neutrophils responses to bactetial PAMPs,
specifically the up-regulation of CD11b and shedding of
L-selectin, were heavily dependent upon the presence of
monocytes [36]. These adhesion molecules are up-regu-
lated in neutrophils of COPD patients but not in cells
from smokers with normal lung function [37]. Future
studies will address, on one hand, the expression of TLR
by neutrophils and, on the other hand, the role of mono-
cytes from COPD patients in the response of neutrophils
from COPD patients to PAMPs and endogenous ligands.
Another, obvious, limitation of our study is that we ana-
lyzed circulating monocytes and not alveolar macro-
phages. We used this approach because of the difficulties
to obtain pulmonary cells during AECOPD and because
we decided to start exploring the role of TLRs in COPD
using the less invasive technique possible. While this
manuscript was under revision, Droemann et al. [38]
reported that alveolar macrophages from COPD patients
and smokers express less TLR-2 than never smokers and
recently we have obtained similar results (Regueiro and
Bengoechea, unpublished findings). Droemann and col-
leagues also examined TLR-2 expression in peripheral
blood monocytes and, in contrast to our results, they did
not find a significant increase in TLR-2 expression in
monocytes from COPD patients [38]. At present we can-
not explain this discrepancy although the patients
recruited in our study are more homogeneous in terms of
age, smoking story and FEV1 than the ones recruited by
Droemann et al [38]. This may explain the differences in
terms of SD between our studies when the results
obtained using flow cytometry are compared which
undoubtedly affect the outcome of the statistical analysis.
Effect of IL-6 on the expression of TLR-2 (panel A) and TLR- 4 (panel B) by human monocytes from never smoker Figure 5
Effect of IL-6 on the expression of TLR-2 (panel A) and TLR-
4 (panel B) by human monocytes from never smoker. Puri-
fied monocytes were incubated in the presence or absence 
of IL-6 (10 ng/ml) and 3 h later TLRs expression was analyzed 
by flow cytometry. Shaded area represents TLRs staining of 
monocytes incubated without IL-6 whereas un-shaded area 
represents TLRs staining of monocytes incubated with IL-6. 
mfi values of cells incubated with isotype matched antibodies 
were 4.3 ± 1.6 whereas mfi values of IL-6-treated cells incu-
bated with isotype matched antibodies were 5.4 ± 1.2 (p > 
0.05). Inset shows results of three different never smokers 
tested in duplicate for each condition studied. The results 
were analyzed by paired two-tailed t test. Symbol: * signifi-
cant difference (p < 0.05) versus non-treated monocytes.
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Care should be taken to directly extrapolate findings
obtained in systemic circulation to the pulmonary com-
partment and vice versa. Monocytes enter into the lungs
both constitutively to keep alveolar macrophage homeos-
tasis as well as during lung inflammation. It will be inter-
esting to study the contribution of monocytes
overexpressing TLR-2 to the lung inflammation of COPD
patients and also the possible effect of lung environment
on the expression of TLR-2 after monocytes have been
recruited. In this context, a recent study using a mice
model of acute lung inflammation [39] shows that
inflammatory recruited monocytes up-regulate gene
expression of chemokines, TNFα and lysosomal proteases
and down-regulate TLR-2 expression. Several studies have
reported that alveolar macrophages from COPD patients
show also these features [38,40].
Our findings may have some clinical implications. First,
we showed that steroids reduce TLR-2 expression in vitro
(fig 4) and, this may happen also in vivo (fig 3) arguing
against the recently postulated steroid-resistance of COPD
[41]. Second, systemic inflammation is a significant con-
tributor to many of the systemic consequences of COPD,
including skeletal muscle dysfunction and cardiovascular
disease [42]. The latter may be particularly relevant in this
context because TLR's have been implicated in the patho-
genesis of atherosclerosis [43]. Thus therapeutic strategies
to control TLR-2-dependent signalling might be useful in
COPD. However, paralysing the TLR-2 -dependent activa-
tion of the innate immunity may increase the risk of bac-
terial infections. An alternative approach would be to
diminish TLR-2 expression. This could be achieved by
blocking the effect of IL-6 on TLR-2 expression using an
antibody against the receptor of this cytokine [44,45] or
blocking the IL-6 intracellular signalling pathway through
the induction of SOCS3, an endogenous signalling repres-
sor of cytokine signals [44,46]. In vitro studies are cur-
rently going on in our laboratory to test the feasibility of
these approaches in COPD.
Conclusion
In summary, our study reveals abnormalities in TLRs
expression in peripheral blood monocytes from COPD
patients, highlights its potential relationship with sys-
temic inflammation in these patients and identifies
potential novel therapeutic targets.
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